Studies ustekinumab treatment for anal fistulas in Crohn's disease patients
Looks at how well individualized ustekinumab treatment works in adults with Crohn's anal fistulas.
Plain-language title generated from the registry record
Registry title: Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease
Key facts
- Where
- Wenzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06739278, who can take part
Where in China
- The Second Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital of Wenzhou Medical University
- Trial code
- NCT06739278
- Record updated
- 18 December 2024
- Original description
This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.Read full original descriptionShow less
Analysis for the Efficacy of Individual Treatment of Perianal Fistulizing Crohn's Disease With Ustekinumab
This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.
Inclusion: Clinical diagnosis of Perianal Fistulizing Crohn's Disease; Receive ustekinumab therapy.
Exclusion: Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs; Combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease, etc; Combined with serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection, etc; Combined with malignant tumor; Clinical data missing ≥30% or no follow-up.